康爱胶囊抗肿瘤作用实验研究

Study on the antitumor action of KangAi capsules

目的研究康爱胶囊急性毒性及对小鼠实体型移植性恶性肿瘤宫颈癌(U14)和腹水型移植性恶性肿瘤肝癌(H22)的抗肿瘤活性。方法测定小鼠灌胃给药LD50,建立实体瘤宫颈癌(U14)和腹水型肝癌(H22)的小鼠模型〔1〕,观察其抗肿瘤作用。结果测得康爱胶囊对小鼠灌胃给药的最大耐受量(MTD)为35.2g·kg-1;1.3g·kg-1,2.5g·kg-1连续灌胃10天对实体瘤宫颈癌(U14)小鼠抑瘤率分别达92.2%(P<0.05),99.3%(P<0.01):2.5g·kg-1,10.0g·kg-1连续灌胃7天对腹水型肝癌(H22)小鼠生命延长率分别达30.7%(P>0.5)、34.6%(P>0.5)。结论康爱胶囊对实体型肿瘤宫颈癌(U14)有明显的抑制作用,且毒性较小。

OBJECTIVE To study the acute toxicity and antitumor action of KangAi capsules in mice. METHODS Tested LD50 of KangAi capsules in mice by p. o administration. Seted up mice models of U14 cancer and H22 cancer,then observed the anticancer action of KangAi. RESULTS The acute toxicity of KangAi capsules was negligible, the results showed that the largest tolerance dose of KangAi capsules in mice was 35.2g·kg^-1 （ two times per day） ,and the U14 cancer were inhibited by KangAi capsules of 1.3 g·kg^-1and 2.5g·kg^-1 with the inhibition rate reaching 92.2% （ P 〈 0. 05 ） and 99.3% （ p 〈 0. 01 ）. But only 30.7% （ P 〉 0. 5 ） and 34.6% （ P 〉 0. 5 ） mice were prolonged by 2.5g·kg^-1 and 10.0g·kg^-1 KangAi capsules with p. o administration. CONCLUSION These resuits showed that the acute toxicity of KangAi capsules was negligible,and obvious anticancer action of KangAi capsules was detected in U14 cancer in mice.